Categories: News

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 11, 2022, to discuss the company’s second quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com/events-and-presentations.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

Genflow Completes Dosing Phase of Canine Gene Therapy Trial

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION…

2 hours ago

President Trump Cleaning Up Biden’s Marijuana Mess – MMJ Preparing to Move FDA Huntington’s Cannabis Trials Forward

Trump Prepares to Clean Up Biden's "Do-Nothing" Marijuana Mess: Why MMJ International Holdings Takes the…

2 hours ago

Meridian Innovation Redefining Low-Cost Thermal Imaging for the AI Era

TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Meridian Innovation's Cheetah thermal imaging sensor claimed this year's Best…

5 hours ago

Atomathic Launches AISIR For Radar — Physical AI Reasoning Technology for Safety-Critical Perception

New White Paper Details the Dual-System Architecture Behind AISIR for Radar™ and How Atomathic Closes…

5 hours ago

Healthcare Payer IT in 2026: Digital Prior Authorization, Enforceable Transparency, and Outcomes-Driven Platforms Spark a New Acquisition Race

CMS compliance deadlines and heightened cybersecurity expectations are accelerating payer interoperability and utilization management modernization…

8 hours ago